$ cat ./records/gates-foundation-backs-path-uniject-prefilled-needle-free-device--2001.txt
Gates Foundation Backs PATH Uniject Prefilled Needle-Free Device for Hepatitis B Birth-Dose Vaccination
[RECORD.TXT] · cat --full
The Gates Foundation supported PATH's Uniject programme, funding field deployment of the Uniject prefilled, single-dose injection device for hepatitis B birth-dose vaccination in Indonesia, Senegal, and other countries. The Uniject device requires no vial, no syringe assembly, and no reconstitution — enabling community health workers with minimal training to safely administer vaccines in homes and village settings without cold chain access at the time of delivery. PATH estimated Uniject-based hepatitis B birth-dose programmes prevented an estimated 5.5 million deaths over 20 years.
Source: https://www.path.org/our-impact/case-studies/uniject-prefilled-injection-device/
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Microsoft enters business software with the $1.1 billion Great Plains deal
Next →
Gates Foundation Leads Global Measles and Rubella Elimination Initiative
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.